Persistent CD20-negative primary cutaneous marginal zone lymphoma after treatment with intralesional rituximab therapy.
Lozzi
Gian Piero
GP
Coletti
Gino
G
Peris
Ketty
K
D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D058846:Antibodies, Monoclonal, Murine-Derived; D018951:Antigens, CD20 / Q000378:metabolism*; D002081:Buttocks; D003131:Combined Modality Therapy; D006801:Humans; D015552:Injections, Intralesional; D008223:Lymphoma / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D008297:Male; D008875:Middle Aged; D012008:Recurrence; D000069283:Rituximab; D012878:Skin Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D013848:Thigh
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D018951:Antigens, CD20; D000069283:Rituximab